Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Equillium stock | $5.63

Learn how to easily invest in Equillium stock.

Equillium Inc is a biotechnology business based in the US. Equillium shares (EQ) are listed on the NASDAQ and all prices are listed in US Dollars. Equillium employs 31 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Equillium

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – EQ – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Equillium stock price (NASDAQ: EQ)

Use our graph to track the performance of EQ stocks over time.

Equillium shares at a glance

Information last updated 2021-10-23.
Latest market close$5.63
52-week range$3.47 - $11.33
50-day moving average $6.16
200-day moving average $6.08
Wall St. target price$14.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.31

Buy Equillium shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Equillium stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Equillium price performance over time

Historical closes compared with the close of $5.63 from 2021-10-26

1 week (2021-10-20) -4.09%
1 month (2021-09-27) -16.72%
3 months (2021-07-27) -3.60%
6 months (2021-04-27) -8.46%
1 year (2020-10-27) -2.26%
2 years (2019-10-25) 73.23%
3 years (2018-10-26) 14.85
5 years (2016-10-23) N/A

Equillium financials

Gross profit TTM $0
Return on assets TTM -28.65%
Return on equity TTM -58.17%
Profit margin 0%
Book value $2.89
Market capitalisation $172.2 million

TTM: trailing 12 months

Shorting Equillium shares

There are currently 506,990 Equillium shares held short by investors – that's known as Equillium's "short interest". This figure is 21.3% down from 643,970 last month.

There are a few different ways that this level of interest in shorting Equillium shares can be evaluated.

Equillium's "short interest ratio" (SIR)

Equillium's "short interest ratio" (SIR) is the quantity of Equillium shares currently shorted divided by the average quantity of Equillium shares traded daily (recently around 98444.660194175). Equillium's SIR currently stands at 5.15. In other words for every 100,000 Equillium shares traded daily on the market, roughly 5150 shares are currently held short.

However Equillium's short interest can also be evaluated against the total number of Equillium shares, or, against the total number of tradable Equillium shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Equillium's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Equillium shares in existence, roughly 20 shares are currently held short) or 0.0314% of the tradable shares (for every 100,000 tradable Equillium shares, roughly 31 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Equillium.

Find out more about how you can short Equillium stock.

Equillium share dividends

We're not expecting Equillium to pay a dividend over the next 12 months.

Equillium share price volatility

Over the last 12 months, Equillium's shares have ranged in value from as little as $3.47 up to $11.33. A popular way to gauge a stock's volatility is its "beta".

EQ.US volatility(beta: 1.5)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Equillium's is 1.4962. This would suggest that Equillium's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Equillium overview

Equillium, Inc. , a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and Phase 1 clinical trial for the treatment of asthma and lupus nephritis. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc.

Frequently asked questions

What percentage of Equillium is owned by insiders or institutions?
Currently 52.375% of Equillium shares are held by insiders and 29% by institutions.
How many people work for Equillium?
Latest data suggests 31 work at Equillium.
When does the fiscal year end for Equillium?
Equillium's fiscal year ends in December.
Where is Equillium based?
Equillium's address is: 2223 Avenida De La Playa, La Jolla, CA, United States, 92037
What is Equillium's ISIN number?
Equillium's international securities identification number is: US29446K1060
What is Equillium's CUSIP number?
Equillium's Committee on Uniform Securities Identification Procedures number is: 29446K106

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site